Establishment Labs Holdings Inc. $ESTA Stock Position Boosted by Union Square Park Capital Management LLC

Union Square Park Capital Management LLC grew its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 16.7% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 105,000 shares of the company’s stock after acquiring an additional 15,000 shares during the period. Establishment Labs comprises approximately 3.4% of Union Square Park Capital Management LLC’s investment portfolio, making the stock its 4th biggest holding. Union Square Park Capital Management LLC’s holdings in Establishment Labs were worth $5,962,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ESTA. Assenagon Asset Management S.A. raised its position in Establishment Labs by 59.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 115,876 shares of the company’s stock valued at $8,445,000 after purchasing an additional 43,164 shares in the last quarter. Simplify Asset Management Inc. grew its position in shares of Establishment Labs by 92.1% during the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock worth $5,313,000 after buying an additional 34,946 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Establishment Labs by 134.3% during the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock valued at $2,154,000 after buying an additional 21,742 shares during the period. AlTi Global Inc. purchased a new position in shares of Establishment Labs during the first quarter valued at $842,000. Finally, Cannon Global Investment Management LLC bought a new stake in shares of Establishment Labs in the first quarter valued at about $738,000. Institutional investors own 72.91% of the company’s stock.

Analysts Set New Price Targets

ESTA has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Citigroup boosted their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Mizuho upped their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Finally, BTIG Research reissued a “buy” rating on shares of Establishment Labs in a report on Monday, July 13th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $90.43.

Establishment Labs Stock Performance

ESTA stock opened at $92.32 on Friday. Establishment Labs Holdings Inc. has a one year low of $33.35 and a one year high of $96.99. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -61.96 and a beta of 1.06. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. The firm has a 50-day simple moving average of $82.58 and a two-hundred day simple moving average of $72.72.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The firm had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same period in the previous year, the company earned ($0.70) EPS. The company’s revenue was up 44.7% on a year-over-year basis. On average, equities analysts forecast that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares in the company, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 182,180 shares of company stock worth $13,369,722 over the last 90 days. Corporate insiders own 9.99% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.